Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Summary

This phase I/II trial is studying the side effects and best dose of obatoclax when given together with bortezomib and to see how well they work in treating patients with relapsed or refractory multiple myeloma. Obatoclax and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving obatoclax together with bortezomib may kill more cancer cells.

Timeline

Start

2008-07

Primary completion

2011-04

Completion

2012-06

Outcome

Outcome not reported

Stopped (Enrollment): “This trial was terminated due to slow accrual and the drug supply of Obatoclax during the phase I; therefore, the phase II portion will never open.”

Drugs

Indications